Mediator Kinase Disruption in MED12-Mutant Uterine Fibroids From Hispanic Women of South Texas.
暂无分享,去创建一个
Min Ju Park | T. Heikkinen | P. Vahteristo | N. Kim | T. Boyer | A. Al-Hendy | R. Schenken | S. Halder | J. McLaughlin | J. Knudtson | Hailian Shen | Courtney M Failor | Fangjian Gao
[1] C. Cho,et al. Current medical treatment of uterine fibroids , 2018, Obstetrics & gynecology science.
[2] Min Ju Park,et al. Oncogenic exon 2 mutations in Mediator subunit MED12 disrupt allosteric activation of cyclin C-CDK8/19 , 2018, The Journal of Biological Chemistry.
[3] T. Falcone,et al. Alternatives to hysterectomy: The burden of fibroids and the quality of life. , 2018, Best practice & research. Clinical obstetrics & gynaecology.
[4] A. Al-Hendy,et al. Selective progesterone receptor modulators for fertility preservation in women with symptomatic uterine fibroids† , 2017, Biology of Reproduction.
[5] J. Carlow,et al. Symptomatic Fibroid Management: Systematic Review of the Literature , 2017, JSLS : Journal of the Society of Laparoendoscopic Surgeons.
[6] Juan Wu,et al. Prevalence and clinical significance of mediator complex subunit 12 mutations in 362 Han Chinese samples with uterine leiomyoma , 2017, Oncology letters.
[7] B. Győrffy,et al. Inhibition of CDK8 mediator kinase suppresses estrogen dependent transcription and the growth of estrogen receptor positive breast cancer , 2017, Oncotarget.
[8] Christopher C. Ebmeier,et al. Identification of Mediator Kinase Substrates in Human Cells using Cortistatin A and Quantitative Phosphoproteomics. , 2016, Cell reports.
[9] Qiwei Yang,et al. The Mechanism and Function of Epigenetics in Uterine Leiomyoma Development , 2016, Reproductive Sciences.
[10] L. Aaltonen,et al. Integrated data analysis reveals uterine leiomyoma subtypes with distinct driver pathways and biomarkers , 2016, Proceedings of the National Academy of Sciences.
[11] Min Ju Park,et al. Somatic MED12 mutations in prostate cancer and uterine leiomyomas promote tumorigenesis through distinct mechanisms , 2016, The Prostate.
[12] M. Abbasi,et al. The study of MED12 gene mutations in uterine leiomyomas from Iranian patients , 2016, Tumor Biology.
[13] U. Surti,et al. Med12 gain-of-function mutation causes leiomyomas and genomic instability. , 2015, The Journal of clinical investigation.
[14] S. Bulun,et al. Endocrinology of uterine fibroids: steroid hormones, stem cells, and genetic contribution , 2015, Current opinion in obstetrics & gynecology.
[15] F. Chibon,et al. MED12 and uterine smooth muscle oncogenesis: State of the art and perspectives. , 2015, European journal of cancer.
[16] A. Clark,et al. Mediator kinase module and human tumorigenesis , 2015, Critical reviews in biochemistry and molecular biology.
[17] S. Shahbazi,et al. Somatic mutational analysis of MED12 exon 2 in uterine leiomyomas of Iranian women. , 2015, American journal of cancer research.
[18] Elizabeth A Stewart,et al. Clinical practice. Uterine fibroids. , 2015, The New England journal of medicine.
[19] Jun Ye,et al. High-resolution melting analysis of MED12 mutations in uterine leiomyomas in Chinese patients. , 2015, Genetic testing and molecular biomarkers.
[20] M. Diamond,et al. Novel MED12 gene somatic mutations in women from the Southern United States with symptomatic uterine fibroids , 2014, Molecular Genetics and Genomics.
[21] C. Simón,et al. Current understanding of somatic stem cells in leiomyoma formation. , 2014, Fertility and sterility.
[22] Min Ju Park,et al. Mutations in Exon 1 Highlight the Role of MED12 in Uterine Leiomyomas , 2014, Human mutation.
[23] L. Aaltonen,et al. Genomics of uterine leiomyomas: insights from high-throughput sequencing. , 2014, Fertility and sterility.
[24] A. Clayton,et al. Uterine cellular leiomyomata with chromosome 1p deletions represent a distinct entity. , 2014, American journal of obstetrics and gynecology.
[25] Min Ju Park,et al. Uterine leiomyoma-linked MED12 mutations disrupt mediator-associated CDK activity. , 2014, Cell reports.
[26] Hiroyuki Aburatani,et al. Multilayer-omics analysis of renal cell carcinoma, including the whole exome, methylome and transcriptome , 2014, International journal of cancer.
[27] J. Coon,et al. Paracrine activation of WNT/β-catenin pathway in uterine leiomyoma stem cells promotes tumor growth , 2013, Proceedings of the National Academy of Sciences.
[28] S. Bulun,et al. Uterine fibroids , 2001, The Lancet.
[29] T. Löning,et al. MED12 mutations in uterine fibroids—their relationship to cytogenetic subgroups , 2012, International journal of cancer.
[30] L. Aaltonen,et al. Somatic MED12 mutations in uterine leiomyosarcoma and colorectal cancer , 2012, British Journal of Cancer.
[31] N. Yoo,et al. Mutational analysis of MED12 exon 2 in uterine leiomyoma and other common tumors , 2012, International journal of cancer.
[32] A. Sivachenko,et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer , 2012, Nature Genetics.
[33] U. Surti,et al. Whole Exome Sequencing in a Random Sample of North American Women with Leiomyomas Identifies MED12 Mutations in Majority of Uterine Leiomyomas , 2012, PloS one.
[34] J. Segars,et al. The estimated annual cost of uterine leiomyomata in the United States. , 2012, American journal of obstetrics and gynecology.
[35] L. Aaltonen,et al. MED12 exon 2 mutations are common in uterine leiomyomas from South African patients , 2011, Oncotarget.
[36] L. Aaltonen,et al. MED12, the Mediator Complex Subunit 12 Gene, Is Mutated at High Frequency in Uterine Leiomyomas , 2011, Science.
[37] J. Massagué,et al. A Smad action turnover switch operated by WW domain readers of a phosphoserine code. , 2011, Genes & development.
[38] J. Bullerdiek,et al. 6p21 rearrangements in uterine leiomyomas targeting HMGA1. , 2010, Cancer genetics and cytogenetics.
[39] N. Chegini,et al. Proinflammatory and Profibrotic Mediators: Principal Effectors of Leiomyoma Development as a Fibrotic Disorder , 2010, Seminars in reproductive medicine.
[40] L. Aaltonen,et al. 7q deletion mapping and expression profiling in uterine fibroids , 2005, Oncogene.